Risk stratification based on screening history: the NELSON lung cancer screening study
- PMID: 28360223
- DOI: 10.1136/thoraxjnl-2016-209892
Risk stratification based on screening history: the NELSON lung cancer screening study
Abstract
Background: Debate about the optimal lung cancer screening strategy is ongoing. In this study, previous screening history of the Dutch-Belgian Lung Cancer Screening trial (NELSON) is investigated on if it predicts the screening outcome (test result and lung cancer risk) of the final screening round.
Methods: 15 792 participants were randomised (1:1) of which 7900 randomised into a screening group. CT screening took place at baseline, and after 1, 2 and 2.5 years. Initially, three screening outcomes were possible: negative, indeterminate or positive scan result. Probability for screening outcome in the fourth round was calculated for subgroups of participants.
Results: Based on results of the first three rounds, three subgroups were identified: (1) those with exclusively negative results (n=3856; 73.0%); (2) those with ≥1 indeterminate result, but never a positive result (n=1342; 25.5%); and (3) with ≥1 positive result (n=81; 1.5%). Group 1 had the highest probability for having a negative scan result in round 4 (97.2% vs 94.8% and 90.1%, respectively, p<0.001), and the lowest risk for detecting lung cancer in round 4 (0.6% vs 1.6%, p=0.001). 'Smoked pack-years' and 'screening history' significantly predicted the fourth round test result. The third round results implied that the risk for detecting lung cancer (after an interval of 2.5 years) was 0.6% for those with negative results compared with 3.7% of those with indeterminate results.
Conclusions: Previous CT lung cancer screening results provides an opportunity for further risk stratifications of those who undergo lung cancer screening.
Trial registration number: Results, ISRCTN63545820.
Keywords: Clinical Epidemiology; Lung Cancer; Smoking cessation; Tobacco and the lung.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: Siemens Germany provided four digital workstations and LungCARE for the performance of 3D measurements of the nodules. Roche diagnostics provided a grant for the performance of proteomics research. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Comment in
-
Defining the path: lung cancer CT screening in Europe.Thorax. 2017 Sep;72(9):778-779. doi: 10.1136/thoraxjnl-2017-210268. Epub 2017 Jul 19. Thorax. 2017. PMID: 28724640 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical